| 王彩云,吕大成,李 羚,王 涛,胡梦笛,徐 璐.miR-483-3p靶向CD44抑制EGFR突变肺癌的作用研究[J].现代生物医学进展英文版,2019,19(14):2601-2608. |
| miR-483-3p靶向CD44抑制EGFR突变肺癌的作用研究 |
| Inhibitory Effect of miR-483-3p on the EGFR-mutant Lung Cancer Via Targeting CD44 |
| Received:April 11, 2019 Revised:April 30, 2019 |
| DOI：10.13241/j.cnki.pmb.2019.14.001 |
| 中文关键词: miR-483-3p 非小细胞肺癌 EGFR酪氨酸激酶抑制剂 CD44 脂质体 |
| 英文关键词: miR-483-3p NSCLC EGFR-TKI CD44 Liposome |
| 基金项目:国家自然科学基金项目(81372522；81773747)；上海市科委基金项目(12ZR1416000；12140901400) |
| Author Name | Affiliation | E-mail | | WANG Cai-yun | Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China | 18865382782@163.com | | LV Da-cheng | Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China | | | LI Ling | Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China | | | WANG Tao | Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China | | | HU Meng-di | Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China | | | XU Lu | Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China | |
|
| Hits: 1256 |
| Download times: 886 |
| 中文摘要: |
| 摘要 目的：探讨miR-483-3p对CD44表达的调控作用及采用脂质体载药系统递送miR-483-3p治疗表皮生长因子(epidermal growth factor receptor，EGFR)突变的非小细胞肺癌(non-small cell lung cancer，NSCLC)的作用。方法：通过miR-483-3p靶基因的数据库发现CD44可能是miR-483-3p的靶基因之一，从结构上及功能上进行验证。在EGFR酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitor, EGFR-TKI)耐药的NSCLC模型中，分别从基因及蛋白水平检测耐药模型及敏感模型中CD44的表达。在HCC827GR移植瘤模型中，采用脂质体-鱼精蛋白-DNA (liposome-polycation-DNA, LPD)载药系统递送miR-483-3p进行治疗，观察肿瘤的生长情况。结果：双荧光素酶报告基因实验及Western blot实验结果显示CD44是miR-483-3p的靶基因之一，且CD44在EGFR-TKI耐药模型中异常高表达(P<0.05)。脂质体载药系统LPD-miRNA-DSPE-PEG符合静脉给药要求，Size为66.93±21 nm，Zeta potential 为8.7±2 mV，PDI (Polydispersity Index)为0.1，递送miR-483-3p后能够抑制HCC827GR移植瘤的生长(P<0.05)。结论：CD44为miR-483-3p的靶基因之一，在耐药模型中高表达，脂质体载药系统给予miR-483-3p能够抑制EGFR-TKI耐药肿瘤的生长。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the regulation of miR-483-3p on CD44 and the treatment of miR-483-3p in EGFR (epidermal growth factor receptor) mutations non-small cell lung cancer (NSCLC) by liposome drug delivery system. Methods: CD44 was found to be one of the target genes of miR-483-3p in the database, and was verified structurally and functionally. In the EGFR Tyrosine Kinase Inhibitor (EGFR-TKI)-resistant model of NSCLC, the expression of CD44 which was detected from gene and protein levels in the resistant and sensitive models. In the xenograft model of HCC827GR, miR-483-3p was delivered for treatment by the liposome- protamine-DNA (LPD) drug delivery system to observe the growth of tumor. Results: Dual-Luciferase Reporter Assay System and Western Blot showed that CD44 was one of the target genes of miR-483-3p, and CD44 was abnormally highly expressed in the EGFR-TKI resistant model in vitro and in vivo(P<0.05). The LPD-miRNA-DSPE-PEG prepared by the liposome drug-loading system met the requirements of intravenous administration, Size: 66.93±21 nm, Zeta potential: 8.7±2 mV, Polydispersity Index: 0.1, which could inhibit the growth of HCC827GR-xenograft-model after delivery of miR-483-3p by LPD-miRNA-DSPE-PEG(P<0.05). Conclusion: CD44 is one of the target genes of miR-483-3p and is highly expressed in the resistant model. The liposome drug delivery system about miR-483-3p can inhibit the growth of EGFR-TKI resistant tumors. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
